A new licensing agreement between Vita Therapeutics and MilliporeSigma (the US and Canada Life Science business of Merck) will see Vita leverage MilliporeSigma’s foundational CRISPR patents to advance its preclinical asset VTA-100 for limb-girdle muscular dystrophy (LGMD2A). VTA-100 utilises this CRISPR genome editing technology to insert a functional copy of the Calpain 3 (CAPN3) gene, […]
